Log In
Print
BCIQ
Print
Print this Print this
 

Zmapp

  Manage Alerts
Collapse Summary General Information
Company Mapp Biopharmaceutical Inc.
DescriptionCombination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationEbola
Indication DetailsTreat Ebola infection
Regulatory Designation

Partner

Defyrus Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today